Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Acarix

0.31 SEK

+1.81 %

Less than 1K followers

ACARIX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.81 %
+15.92 %
+3.17 %
+28.96 %
+23.31 %
+16.79 %
+10.05 %
-77.64 %
-95.81 %

Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary artery disease. The company's product is a non-invasive test that is applied with a patch to the patient to analyze sounds from the heart. The business is conducted primarily within the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The headquarters are located in Malmö.

Read more
Market cap
347.67M SEK
Turnover
158.28K SEK
Revenue
6.2M
EBIT %
-1,070.48 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2
2026

Annual report '25

All
Press releases
ShowingAll content types
Press release11/6/2025, 7:45 AM

Invitation to presentation of Acarix´s third quarter 2025 report

Acarix
Regulatory press release11/6/2025, 7:00 AM

Acarix Publishes Interim Report, Third quarter 2025

Acarix
Regulatory press release10/27/2025, 2:35 PM

Announcement from the general meeting in Acarix AB

Acarix

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release10/24/2025, 1:15 PM

Acarix AB changes Certified Adviser to Tapper Partners AB

Acarix
Press release10/17/2025, 6:30 AM

Acarix responds to G-BA decision on reimbursement in the German market

Acarix
Regulatory press release10/9/2025, 10:15 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB

Acarix
Press release10/7/2025, 7:31 AM

Acarix CADScor® System Gains HealthChoice Reimbursement Coverage

Acarix
Press release9/18/2025, 3:04 PM

Acarix Chairman Jan Poulsen Acquires Shares

Acarix
Press release9/8/2025, 7:45 AM

CEO purchases shares in Acarix

Acarix
Press release8/25/2025, 9:19 AM

Redeye: Acarix Q2 - An eventful quarter

Acarix
Press release8/21/2025, 6:30 AM

Acarix Reports Significant Progress Toward Fixed Reimbursement

Acarix
Regulatory press release8/21/2025, 6:00 AM

Acarix Publishes Interim Report, January – June 2025

Acarix
Press release8/20/2025, 7:45 AM

Acarix and Aalborg University Abstract Accepted for AHA 2025

Acarix
Press release8/18/2025, 9:09 AM

Invitation to presentation of Acarix´s second quarter 2025 report

Acarix
Press release7/28/2025, 7:47 AM

Acarix achieves new Fixed U.S. reimbursement milestone for CADScor at $300.00 USD

Acarix
Regulatory press release7/8/2025, 2:05 PM

Acarix Enters MENA Region with First Major Order, Expanding Global Presence

Acarix
Press release6/26/2025, 7:40 AM

Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor® System in U.S. Emergency Departments

Acarix
Press release6/16/2025, 8:05 AM

Acarix Achieves First Fixed U.S. Reimbursement Milestone for CADScor at $300.00 USD

Acarix
Press release5/19/2025, 1:19 PM

CEO purchases shares in Acarix

Acarix
Press release5/14/2025, 9:15 AM

Redeye: Acarix Q1 - Strong foundation for eventual ramp-up

Acarix
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.